Analytical Pharmacology

摘要 Sidney Kimmel综合癌症中心（SKCCC）分析药理学核心（APC） 提供最先进和具有成本效益的分析化学和临床药理学服务， 自1985年成立以来，一直是会员。APC提供1200个仪表和设施， 位于SKCCC Bunting-Blaustein癌症研究大楼（CRBI）一楼的2英尺实验室。具体 该核心的目的是：1）提供临床试验和临床前研究设计方面的专业知识，重点是 关键药理学终点; 2）提供最先进的药物非临床研究质量管理规范（GLP）-质量、成本- 有效的服务，以定量生物流体中的抗癌药物和代谢物;以及3）提供 药代动力学/药效学数据分析和解释，长期愿景是提供 在临床前和临床环境中用于药物开发的决策工具。装甲运兵车拥有四个超- 高效液相色谱/高效液相色谱（UPLC/HPLC）仪器， 紫外/荧光（1）、三级四重质谱仪（3）和带离子阱的QTrap系统 能力（1）用于更复杂的药物代谢研究。APC每年分析超过3，200个样品， 每年开发15种新方法，并为所有CCSG项目的45名教职员工提供服务， 大多数用户都有同行评审的资金。在过去的五年里，APC已经成为一个 跨翻译谱的关键组成部分，提供分析方法开发服务（四个 手稿）、药物发现（7份手稿）、临床前研究（26份手稿）和临床试验（31份 手稿）。APC在五年内参与了42项以癌症为重点的赠款的提交， 在约翰霍普金斯早期治疗药物临床试验网络的成功应用中发挥了重要作用 (UM1)和艾滋病联盟（UM 1），并担任成人脑肿瘤的第二个实验室 联合体（UM 1）。所要求的CCSG资金将支持提供咨询服务的人员 与分析开发、方案设计和数据解释相关，并确保仪器 适当维护和有效利用。 SKCCC托管核心 报告期：2015年1月1日至2015年12月31日

ABSTRACT The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Analytical Pharmacology Core (APC) has offered state-of-the-art and cost-effective analytical chemistry and clinical pharmacology services to members continuously since its inception in 1985. The APC provides instrumentation and facilities in a 1,200 ft2 laboratory on the first floor of the SKCCC Bunting-Blaustein Cancer Research Building (CRBI). The specific aims of this Core are to: 1) provide expertise in clinical trial and preclinical study design, with a focus on critical pharmacological endpoints; 2) provide state-of-the-art, Good Laboratory Practice (GLP)-quality, cost- effective services to quantitate anticancer drugs and metabolites in biological fluids; and 3) provide pharmacokinetic/ pharmacodynamic data analysis and interpretation, with the long-term vision of providing decision tools for drug development in both the preclinical and clinical settings. The APC houses four ultra- performance liquid chromatography/high-performance liquid chromatography (UPLC/HPLC) instruments with a UV/fluorescence (1), triple-stage quadruple mass spectrometer (3) and a QTrap system with ion trap capabilities (1) for more intricate drug metabolism studies. The APC analyzes over 3,200 samples/year, develops 15 new methods per year and serves over 45 faculty members across all of the CCSG Programs, with the majority of the users having peer-reviewed funding. During the last five years, the APC has become a critical component across the translational spectrum, providing services in analytical method development (four manuscripts), drug discovery (seven manuscripts), preclinical studies (26 manuscripts) and clinical trials (31 manuscripts). The APC has participated in the submission of 42 cancer-focused grants over five years, played a major role in the successful applications for the Johns Hopkins Early Therapeutics Clinical Trials Network (UM1) and AIDS Malignancy Consortium (UM1), and served as a second laboratory for the Adult Brain Tumor Consortium (UM1). The requested CCSG funding will support personnel who provide consultative services related to assay development, protocol design and data interpretation, and ensure that instrumentation is suitably maintained and utilized efficiently. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015